Amneal Pharmaceuticals, Inc. (AMRX) Stock

About Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. (AMRX) stock trades at $20.38 with a market capitalization of $6.51B. The stock is valued at a price-to-earnings (P/E) ratio of 38.55, price-to-book of 185.39, price-to-sales of 1.96. Over the past 52 weeks the stock has ranged between $9.92 and $21.18, and currently trades 3.8% below its 52-week high.

On profitability, Amneal Pharmaceuticals, Inc. generates a return on equity (ROE) of -326.75% (negative, reflecting a net loss), return on capital employed of 13.94%, an operating margin of 19.57%, a net profit margin of 5.05%.

Amneal Pharmaceuticals, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Amneal Pharmaceuticals, Inc. reported revenue of $1.0B rising to $3.0B, a change of +196.6% across 10 years. Compounded, revenue has grown 8.7% a year over five years, 10.9% over three, 8.1% over the last twelve months. Net profit fell to $72.0M.

Operating margin went from 28.0% in 2016 to 14.0% in 2025, a fall of 14.0 percentage points. The most recent net margin is 5.05%. On a trailing twelve-month basis to Jun '26, revenue is $3.1B and net profit $157.0M.

Borrowings rose from $1.2B to $2.7B, cash from operations was $340.0M in the latest year, positive in 10 of the last 10.

Return on equity has averaged -90.9% over five years, and was -101.4% in the most recent year.

The share price itself has compounded at 18.1% a year over five years, 87.2% over three, 65.8% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Amneal Pharmaceuticals, Inc. (AMRX) — frequently asked questions